Evidence map›Paper›PMID 36797775›Full record

ArticleBiomaterials research2023

Effect of chitooligosaccharide on the inhibition of SARS-CoV-2 main protease.

Qian Wang, Yuanyuan Song, Mungu Kim, Sei Kwang Hahn, Ge Jiang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomaterials research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.2field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 12 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Qian Wang *Bioengineering College, Dalian University, 10 Xuefu Street, Jinzhou District, Dalian, 116600, Liaoning, China.
Yuanyuan Song *Bioengineering College, Dalian University, 10 Xuefu Street, Jinzhou District, Dalian, 116600, Liaoning, China.
Mungu KimDepartment of Materials Science and Engineering, Pohang University of Science and Technology (POSTECH), 77 Cheongam-Ro, Nam-Gu, Pohang, 790-784, Gyeongbuk, Korea.
Sei Kwang HahnDepartment of Materials Science and Engineering, Pohang University of Science and Technology (POSTECH), 77 Cheongam-Ro, Nam-Gu, Pohang, 790-784, Gyeongbuk, Korea. skhanb@postech.ac.kr.ORCID http://orcid.org/0000-0002-7718-6259
Ge JiangBioengineering College, Dalian University, 10 Xuefu Street, Jinzhou District, Dalian, 116600, Liaoning, China. jiangge1004@163.com.
Dalian University · CNPohang University of Science and Technology · KR

Funding

Dalian Science and Technology Innovation Fund 2021JJ13SN62Ministry of Science and ICT, South Korea 2020R1A2C3014070
6 · The paper itself

Abstract

backgroundThe main protease (Mpro) is a crucial target for severe acute respiratory syndrome coronavirus (SARS-CoV-2). Chitooligosaccharide (CS) has broad-spectrum antiviral activity and can effectively inhibit the activity of SARS-CoV. Here, based on the high homology between SARS-CoV-2 and SARS-CoV, this study explores the effect and mechanism of CS with various molecular weights on the activity of SARS-CoV-2 Mpro.

methodsWe used fluorescence resonance energy transfer (FRET), UV-Vis, synchronous fluorescence spectroscopy, circular dichroism (CD) spectroscopy and computational simulation to investigate the molecular interaction and the interaction mechanism between CS and SARS-CoV-2 Mpro.

resultsFour kinds of CS with different molecular weights significantly inhibited the activity of Mpro by combining the hydrogen bonding and the salt bridge interaction to form a stable complex. Glu166 appeared to be the key amino acid. Among them, chitosan showed the highest inhibition effect on Mpro enzyme activity and the greatest impact on the spatial structure of protein. Chitosan would be one of the most potential anti-viral compounds.

conclusionThis study provides the theoretical basis to develop targeted Mpro inhibitors for the screening and application of anti-novel coronavirus drugs.

Indexed as

ChitooligosaccharideMolecular dockingMproSARS-CoV-2Spectroscopy

Identifiers

PMID36797775
PMCPMC9935244
OpenAlexW4321015518

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.